In Depth 23 May 2024
Is prime editing ready for prime time?
Prime editing, a more advanced version of CRISPR/Cas9 technology, has been greenlit by the FDA to begin the first-ever clinical trial for this technology.
- Latest Posts
Best in Biotech 23 May 2024
10 notable pharma and biotech venture capital arms
Discover 10 big pharma and biotech companies that have spun out their own venture capital arms to invest in startups in the industry.
In Depth 22 May 2024
The undruggable cancer target: KRAS inhibitors move ahead in the clinic
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio’s spinout.
Best in Biotech 21 May 2024
Eight companies spearheading Philadelphia’s biotech industry
Often called the Cellicon Valley due to its focus on cell and gene therapy, discover eight Philadelphia biotech companies to know about.
Powering up biologics development using mammalian cell lines
Explore how mammalian cell lines drive biopharmaceutical innovation, acting as mini-factories for vital biotherapeutics and vaccines.
Inside Labiotech 20 May 2024
Participate in the 2024 Labiotech Reader Survey for a chance to win a €250 or $250 Amazon gift card!
We would like to learn more about you. Participate in the 2024 Labiotech Reader Survey for a chance to win a €250 or $250 Amazon gift card!
ADVERTISEMENT
ADVERTISEMENT
Expert Advice 17 May 2024
How to use LinkedIn to ace your biotech job search and advance your career
LinkedIn is the most powerful tool to develop your career in the biotech industry. Delve into the strategies to use it efficiently.
Podcast 17 May 2024
Isarna Therapeutics revolutionizes ophthalmology with antisense oligonucleotides
German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications. Isarna Therapeutics’s lead compound, ISTH0036, is in […]
Expert Advice 16 May 2024
Types of clinical trial designs: The essentials
The average journey of a drug from trial to market is 10.5 years. Delve into the different clinical trials designs and their specificities.
Best in Biotech 16 May 2024
Five orthobiologics companies leading the way in the field
Discover five of the top orthobiologics companies leading the way in the field, as the market is set to grow in the next few years.
In Depth 15 May 2024
Drugs for IgA nephropathy on the rise in the clinic
As we observed IgA Nephropathy Awareness Day on May 14th, let us take a look at ongoing clinical trials for drugs that aim to make patient lives better.
Best in Biotech 14 May 2024
Six biotechs in Belgium making leaps in the clinic
Meet the most successful biotech companies in Belgium, a country that makes a huge contribution to the biotech industry.
ADVERTISEMENT
